eMedicine Specialties > Nephrology > Chronic Kidney Disease

Encephalopathy, Uremic

Author: James W Lohr, MD, Fellowship Program Director, Professor, Department of Internal Medicine, Division of Nephrology, State University of New York at Buffalo
Contributor Information and Disclosures

Updated: Oct 29, 2009

Introduction

Background

Uremic encephalopathy is an organic brain disorder. It develops in patients with acute or chronic renal failure, usually when creatinine clearance (CrCl) levels fall and remain below 15 mL/min.1,2,3

Manifestations of this syndrome vary from mild symptoms (eg, lassitude, fatigue) to severe symptoms (eg, seizures, coma). Severity and progression depend on the rate of decline in renal function; thus, symptoms are usually worse in patients with acute renal failure. Prompt identification of uremia as the cause of encephalopathy is essential because symptoms are readily reversible following initiation of dialysis.4,5

Pathophysiology

Uremic encephalopathy has a complex pathophysiology, and many toxins that accumulate in kidney failure may be contributive. Parathyroid hormone (PTH) likely contributes to uremic encephalopathy.6

Secondary hyperparathyroidism, which occurs in kidney failure, causes an increase in calcium content in the cerebral cortex. In animal models with uremia, EEG changes were typical of those observed in patients with renal failure. In uremic patients with secondary hyperparathyroidism, EEG changes have been shown to improve after medical suppression of PTH or parathyroidectomy.

The specific mechanism by which PTH causes disturbance in brain function is unclear, but it may be caused by increases in intracellular concentration of calcium in brain cells. However, since the encephalopathy improves with dialysis, which does not have a marked effect on PTH levels, hyperparathyroidism is not thought to be the main cause.

Another theory about the etiology of uremic encephalopathy suggests imbalances of neurotransmitter amino acids within the brain. During the early phase of uremic encephalopathy, plasma and cerebrospinal fluid (CSF) determinations indicate that levels of glycine increase and levels of glutamine and GABA decrease; additionally, alterations occur in metabolism of dopamine and serotonin in the brain, which may lead to early symptoms (eg, sensorial clouding). As uremia progresses, it has been proposed that the accumulation of guanidino compounds results in activation of excitatory N-methyl-D-aspartate (NMDA) receptors and inhibition of inhibitory GABA receptors, which may cause myoclonus and seizures.4,7,8

A study of acute kidney injury in mice found evidence of a blood-brain barrier disruption from such injury, with increased neuronal pyknosis and microgliosis. In addition, proinflammatory chemokines were increased in brain tissue.9

Numerous other uremic toxins may contribute to uremic encephalopathy, but there has been a notable lack of research in this area. Although the encephalopathy correlates roughly with BUN level, urea is not itself thought to be causative.

Frequency

United States

Most patients with a CrCl level less than 10% of normal probably develop some degree of encephalopathy; however, they may not be clearly symptomatic. In one pediatric study, encephalopathy occurred in 40% of the children with a BUN level greater than 90 mg/dL. As the BUN level increased, the likelihood of these children developing convulsions increased.

Mortality/Morbidity

Symptoms include somnolence and decreased mentation. Asterixis is usually present. These findings are reversible following initiation of dialysis and recovery of renal function in patients with acute renal failure. Symptoms are also reversible following the institution of dialysis or renal transplantation in patients with chronic renal insufficiency. The severe complications (ie, seizures, coma) can lead to death. Early recognition of encephalopathy in the setting of decreased renal function is crucial to prevent morbidity or mortality.

Race

No racial predilection exists.

Sex

No significant association between sex and incidence exists.

Age

Uremic encephalopathy may develop at any age.

Clinical

History

  • Early symptoms
    • Anorexia
    • Nausea
    • Restlessness
    • Drowsiness
    • Diminished ability to concentrate
    • Slowed cognitive functions
  • More severe symptoms
    • Vomiting
    • Emotional volatility
    • Decreased cognitive function
    • Disorientation
    • Confusion
    • Bizarre behavior
  • As uremic encephalopathy progresses, patients may develop myoclonus, asterixis, seizures, stupor, and coma.

Physical

  • Altered mental status (confusion)
  • Cranial nerve signs (nystagmus)
  • Papilledema
  • Hyperreflexia, clonus, asterixis
  • Stupor
  • Coma occurs only if uremia remains untreated and progresses.

Causes

Uremic encephalopathy may occur in a patient affected with acute kidney injury or chronic kidney failure of any etiology.

More on Encephalopathy, Uremic

Overview: Encephalopathy, Uremic
Differential Diagnoses & Workup: Encephalopathy, Uremic
Treatment & Medication: Encephalopathy, Uremic
Follow-up: Encephalopathy, Uremic
References

References

  1. Bolton CF, Young GB. Encephalopathy of chronic renal failure. In: Neurological Complications of Renal Disease. 1990:49-74.

  2. Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg. Dec 2004;107(1):1-16. [Medline].

  3. Arieff AI. Nervous system manifestations of renal failure. In: Schrier RW, ed. Diseases of the Kidney. Lippincott; 2007:2460-2482.

  4. Biasioli S, D'Andrea G, Feriani M, Chiaramonte S, Fabris A, Ronco C, et al. Uremic encephalopathy: an updating. Clin Nephrol. Feb 1986;25(2):57-63. [Medline].

  5. Biasioli S. Neurologic aspects of dialysis. In: Nissenson A, Fine R, eds. Clinical Dialysis. 2005:855-876.

  6. Moe SM, Sprague SM. Uremic encephalopathy. Clin Nephrol. Oct 1994;42(4):251-6. [Medline].

  7. Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M. Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J Neurochem. Feb 2006;96(4):1051-9. [Medline].

  8. De Deyn PP, Vanholder R, Eloot S, et al. Guanidino compounds as uremic (neuro)toxins. Semin Dial. Jul-Aug 2009;22(4):340-5. [Medline].

  9. Liu M, Liang Y, Chigurupati S, Lathia JD, Pletnikov M, Sun Z, et al. Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol. Jul 2008;19(7):1360-70. [Medline].

  10. Yamamoto T, Satomura K, Okada S, et al. Risk factors for neurological complications in complete hemolytic uremic syndrome caused by Escherichia coli O157. Pediatr Int. Apr 2009;51(2):216-9. [Medline].

Further Reading

Keywords

uremic encephalopathy, encephalopathy, uremia, encephalopathies, metabolic encephalopathy, treatment encephalopathy, uremic syndrome

Contributor Information and Disclosures

Author

James W Lohr, MD, Fellowship Program Director, Professor, Department of Internal Medicine, Division of Nephrology, State University of New York at Buffalo
James W Lohr, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Nephrology, and Central Society for Clinical Research
Disclosure: Nothing to disclose.

Medical Editor

Donald A Feinfeld, MD, FACP, FASN, Consulting Staff, Division of Nephrology & Hypertension, Beth Israel Medical Center
Donald A Feinfeld, MD, FACP, FASN is a member of the following medical societies: American Academy of Clinical Toxicology, American Society of Hypertension, American Society of Nephrology, and National Kidney Foundation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Ajay K Singh, MB, MRCP, MBA, Associate Professor of Medicine, Harvard Medical School; Clinical Chief, Renal Division, Director of Dialysis, Brigham and Women's Hospital; Consulting Staff, Faulkner Hospital
Disclosure: Nothing to disclose.

CME Editor

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine
Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association
Disclosure: Abbott Grant/research funds Speaking and teaching; Genzyme Honoraria Consulting; Amgen Honoraria Speaking and teaching; Ortho Biotech Honoraria Speaking and teaching

Chief Editor

Vecihi Batuman, MD, FACP, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System
Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.